BiondVax to lease facility in Jerusalem BioPark
BiondVax Pharmaceuticals signed an agreement to lease approximately 1800m2 in the Jerusalem BioPark, or JBP, located in the Ein Kerem Hadassah campus, next to Hadassah University Hospitals and Hebrew University's Medical School. The mid-sized facility is planned to have capacity to annually produce tens of millions of doses of M-001 either in single-dose syringe or in bulk. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Planning and design of the facility by a leading engineering company has begun, and while construction will begin soon, the agreement calls for BiondVax to begin lease payments in October 2018. Costs of building and operating the facility are partially supported by a previously announced grant from Israel's Ministry of Economy and Industry and a EUR20M agreement with the European Investment Bank.